An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research reported at the 56th annual meeting of the American Society of Hematology, in San Francisco, California. These patients have a poor prognosis and few options.
Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to senior author Anthony Letai, MD, PhD, of Dana-Farber Cancer Institute in Boston, Massachusetts.
The phase II multicenter trial was the first time ABT-199 was used in patients with relapsed or resistant AML. These patients often have received many previous treatments with chemotherapy or hypomethylating agents, and are too debilitated to undergo aggressive therapies such as more intense chemotherapy or stem cell transplants.
The trial, involving 32 patients, was launched on the basis of preclinical studies from Letai’s and Marina Konopleva’s laboratories at Dana-Farber Cancer Institute and the University of Texas MD Anderson Cancer Center in Houston, showing that ABT-199 could kill AML cell lines, patient AML cells, and patient-derived AML cells implanted into mice. ABT-199 targets the cancer survival protein BCL-2, which has been linked to resistance and poor prognosis in patients with AML.
Patients in the open-label trial ranged in age from 19 to 84 years and the median age was 71 years.
At the first assessment 4 weeks after treatment, two patients had a complete response and four had complete responses with incomplete recovery of normal blood cell forms; one of the four achieved a complete response by week 20, the investigators reported. Six of the 32 patients had at least a 50% reduction in bone marrow blasts.
No patients died as a result of adverse events from the treatment.
The researchers concluded that ABT-199 as a single agent has considerable clinical activity in patients with relapsed or resistant AML, and patients with mutations in IDH genes may be particularly sensitive to the drug.
Letai noted that dose-limiting toxicity was not reached, leaving open the possibility of higher doses in further trials. The next step, he said, is to carry out trials combining ABT-199 with other agents. These trials are currently opening at several sites, including at Dana-Farber.
Updated on January 22, 2015